Practical Management of the GYN-Oncology Patient Discussing Real Life Cases

Eric Pujade-lauraine Centre des Cancers de la Femme et Recherche Clinique Université Paris Descartes

Case study

- 49 yr old woman, vaginal bleeding. Clinical examination + MRI = tumor of the cervix-6.4 cm- no evidence of parametrial invasion nor vaginal- biopsy: adenocarcinoma
- Laparoscopic para-aortic lymph node dissection: negative
- Chemoradiation (cisplatin)




- 1 year later: relapse in the pelvis and peritoneum. Left hydronephrosis. Normal renal function.
- Pelvic MRI: 6cm mass between bladder and rectum without sign of mucosa invasion

Three Decades: Recurrent and Metastatic Cervical Cancer

- Cisplatin (Cis) 50 mg/m2 plus paclitaxel (Pac) 135 mg/m2 is standard therapy (GOG)
 - -Alternative is carboplatin plus paclitaxel
- Gynecologic Oncology Group (GOG) 204 (2009)
 - Phase III randomized trial of 4 platinum-based chemotherapy doublets: Cisplatin plus paclitaxel remained standard for GOG
- Majority of patients with recurrent cervical cancer treated with cisplatin-based chemoradiation for locally advanced disease
- New therapeutic options needed:
 - -Non-platinum chemotherapy doublets?
 - -Anti-angiogenesis therapy?

Tewari KS, et al. *Curr Oncol Rep.* 2005;7(6):419-434. Monk BJ, et al. *J Clin Oncol.* 2007;25(20):2952-2965. Tewari KS, et al. *Onkologie.* 2008;32(10):552-554. *Monk BJ, et al. *J Clin Oncol.* 2009;27(28):4649-4655. Tewari KS, et al. *Semin Oncol.* 2009;36(2):170-180. Tewari KS, et al. *Clin Adv Hematol Oncol.* 2010;8(2):108-115. Tewari KS. *Am J Hematol Oncol.* 2010;9:31-34. Tewari KS. *Clin Ovarian Cancer.* 2011;4:90-93.


GOG 240: Schema



CR, complete response; PD, progressive disease; PS, performance status; q21d, every 21 days; Rx, treatment

National Institutes of Health. Available at: http://clinicaltrials.gov/ct2/show/NCT00803062. Accessed January 7, 2015.

GOG 240.6: Final Protocol-Specified OS ChemoRx vs ChemoRx Plus Bev



Tewari KS, et al. Ann Oncol. 2014;25(Suppl 4): Abstract LBA26.


Moore Criteria

- Performance status>0
- Pelvic disease
- African-American ancestry
- Disease-free interval<1 year
- Prior platinum exposure

Prognosis according to Moore Criteria


- Low risk: 0-1 factors
- Mid risk: 2-3 factors
- High risk: 4-5 factors

Overall Survival by regimen




Tewari et al.Clin Cancer Res; 21(24) December 15, 2015

Overall Survival by regimen



Tewari et al.Clin Cancer Res; 21(24) December 15, 2015

Overall Survival by risk regimen



Tewari et al.Clin Cancer Res; 21(24) December 15, 2015

Bevacizumab approved in recurrent/metastatic cervix cancer

• FDA: August 14, 2014

- EMA: April 8, 2015
- France

GOG 240.2: OS and Prognostic Factors

Subgroup	No. of patients		Hazard ratio			
Age	Age ≤40 years	112				
	40 <age td="" years<="" ≤48=""><td>111</td><td></td><td></td><td></td><td></td></age>	111				
	48 <age td="" years<="" ≤56=""><td>108</td><td></td><td></td><td></td><td></td></age>	108				
	56 years <age< td=""><td>121</td><td></td><td></td><td></td><td></td></age<>	121				
Performance status	0	263				
	1	189	_			
Prior platinum RT	Νο	115				
·	Yes	337		-		
Disease status	Advanced	76		-		
	Recurrent/persistent	376		_		
Topotecan treatment	Νο	229				
	Yes	223		—		
Race	Not black	392		-		
	Black	60				
Histology	Adenocarcinoma	86			_	
	Adenosquamous	44				
	Other	12				
	Squamous	310				
Pelvic disease	No	210		-		
	Yes	242		-		
Overall		452	0.0 0.5	1.0 1.5	2.0	2.5
		←	- Experimental Bett	ter Control Bett	er —	\rightarrow

Tewari KS, et al. *J Clin Oncol*. 2013;31(Suppl): Abstract 3.


GOG 240.2: Treatment Exposure and Specific Adverse Events (AEs)

Adverse Event, n (%)	Chemo Alone (n = 219)	Chemo + Bev (n = 220)	
Grade 5 AE(s)	4 (1.8)	4 (1.8)	
GI events, non-fistula (grade ≥2)	96 (44)	114 (52)	
GI fistula (grade ≥3)*	0 (0)	7 (3)	
GI perforation (grade ≥3)	0 (0)	5 (2)	
GU fistula (grade ≥3)*	1 (0)	6 (2)	
Pain (grade ≥2)	62 (28)	71 (32)	
Hypertension (grade ≥2)*	4 (2)	54 (25)	
Proteinuria (grade ≥3)	0 (0)	4 (2)	
Neutropenia (grade ≥4)*	57 (26)	78 (35)	
Febrile neutropenia (grade <u>></u> 3)	12 (5)	12 (5)	
Thromboembolism (grade ≥3)*	3 (1)	18 (8)	
Bleeding CNS (any grade)	0 (0)	0 (0)	
GI (grade ≥3)	1 (0)	4 (1)	
GU (grade ≥3)	1 (0)	6 (3)	

**P*<.05

Tewari KS, et al. J Clin Oncol. 2013;31(Suppl): Abstract 3.

Vaginal Fistulae




In a separate analysis of the GOG 240 study, all fistulae events were re-graded:

 None of the fistulae were associated with peritonitis, sepsis or death. Among the patients who developed GI-vaginal fistulae, all (100%) had received prior pelvic radiation therapy compared to 80% in the overall population.

Willmott L, et al. Presented at the 15th Biennial Meeting of the International Gynecologic Cancer Society; 8-11 November, 2014: Melbourne, Australia. [abstract] CT, chemotherapy; GI, gastrointestinal; GU, genitourinary

GOG 240.3: HRQoL Mean FACT-Cx TOI

Mean FACT-Cx TOI Scores



Penson RT, et al. *Eur J Cancer.* 2013;49(Suppl 3): Abstract LBA42.

Who is the Best Candidate for Bevacizumab?

GOG 240: Eligibility Criteria

- Recurrent/persistent or metastatic disease
- Frontline excluding chemotherapy with radiation
- Squamous cell carcinoma (SCCA), adenocarcinoma (AC), adenosquamous carcinoma (AS)
- GOG performance status 0-1
- Normal renal function (Cr < 1.3)
- No bleeding or nonhealing ulcer, other nonhealing wound, or fistula
- Malnutrition corrected

GOG 240.2: Conclusions

Bevacizumab plus chemotherapy significantly improves OS in stage IVB, recurrent or persistent cervical carcinoma

- Nearly 4-month improvement in OS is clinically significant
- Increase in median PFS and overall response rate are also demonstrated
- Benefit seen even when recurrent disease is in irradiated pelvis
- Bevacizumab treatment is associated with a higher rate of AEs
 - 3% to 8% rate of known bevacizumab-related Aes
 - The improvement in OS with bevacizumab treatment was not accompanied by a significant decrease in HRQoL



GOG 240.1: Toxicity Cis-Pac Backbone vs Topo-Pac Backbone

		Grade 0	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
Leukopenia	Cis-Pac	45	27	70	60	10	0
	Торо-Рас	30	28	42	71	33	0
Nausea	Cis-Pac	82	78	36	16	0	0
	Topo-Pac	103	71	26	4	0	0
Vomiting	Cis-Pac	145	29	28	10	0	0
	Topo-Pac	161	27	11	5	0	0
Metabolic	Cis-Pac	115	42	28	26	1	0
	Topo-Pac	130	35	26	11	2	0
Neurosensory	Cis-Pac	96	65	35	16	0	0
	Торо-Рас	87	82	30	5	0	0
Allergy	Cis-Pac	172	16	17	7	0	0
	Topo-Pac	193	7	1	3	0	0